These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36980614)

  • 1. Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications.
    Nguyen TT; Hamdan D; Angeli E; Feugeas JP; Le QV; Pamoukdjian F; Bousquet G
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
    Bui TO; Dao VT; Nguyen VT; Feugeas JP; Pamoukdjian F; Bousquet G
    Eur Urol; 2022 Apr; 81(4):349-361. PubMed ID: 34991918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical reliability of genomic data obtained from spinal metastatic tumor samples.
    Barzilai O; Martin A; Reiner AS; Laufer I; Schmitt A; Bilsky MH
    Neuro Oncol; 2022 Jul; 24(7):1090-1100. PubMed ID: 34999837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases.
    Huang RSP; Haberberger J; McGregor K; Mata DA; Decker B; Hiemenz MC; Lechpammer M; Danziger N; Schiavone K; Creeden J; Graf RP; Strowd R; Lesser GJ; Razis ED; Bartsch R; Giannoudis A; Bhogal T; Lin NU; Pusztai L; Ross JS; Palmieri C; Ramkissoon SH
    Oncologist; 2021 Oct; 26(10):835-844. PubMed ID: 34105210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases.
    Hohensee I; Lamszus K; Riethdorf S; Meyer-Staeckling S; Glatzel M; Matschke J; Witzel I; Westphal M; Brandt B; Müller V; Pantel K; Wikman H
    Am J Pathol; 2013 Jul; 183(1):83-95. PubMed ID: 23665199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A system for detecting high impact-low frequency mutations in primary tumors and metastases.
    Anjanappa M; Hao Y; Simpson ER; Bhat-Nakshatri P; Nelson JB; Tersey SA; Mirmira RG; Cohen-Gadol AA; Saadatzadeh MR; Li L; Fang F; Nephew KP; Miller KD; Liu Y; Nakshatri H
    Oncogene; 2018 Jan; 37(2):185-196. PubMed ID: 28892047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative genomic analysis of primary tumors and metastases in breast cancer.
    Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
    Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer.
    Richard F; Majjaj S; Venet D; Rothé F; Pingitore J; Boeckx B; Marchio C; Clatot F; Bertucci F; Mariani O; Galant C; Eynden GVD; Salgado R; Biganzoli E; Lambrechts D; Vincent-Salomon A; Pruneri G; Larsimont D; Sotiriou C; Desmedt C
    Clin Cancer Res; 2020 Dec; 26(23):6254-6265. PubMed ID: 32943456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in Genomic Alterations Between Brain Metastases and Primary Tumors.
    Dono A; Takayasu T; Yan Y; Bundrant BE; Arevalo O; Lopez-Garcia CA; Esquenazi Y; Ballester LY
    Neurosurgery; 2021 Feb; 88(3):592-602. PubMed ID: 33369669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance of PTEN loss in brain metastasis formation in breast cancer patients.
    Wikman H; Lamszus K; Detels N; Uslar L; Wrage M; Benner C; Hohensee I; Ylstra B; Eylmann K; Zapatka M; Sauter G; Kemming D; Glatzel M; Müller V; Westphal M; Pantel K
    Breast Cancer Res; 2012 Mar; 14(2):R49. PubMed ID: 22429330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.
    Wang P; Bahreini A; Gyanchandani R; Lucas PC; Hartmaier RJ; Watters RJ; Jonnalagadda AR; Trejo Bittar HE; Berg A; Hamilton RL; Kurland BF; Weiss KR; Mathew A; Leone JP; Davidson NE; Nikiforova MN; Brufsky AM; Ambros TF; Stern AM; Puhalla SL; Lee AV; Oesterreich S
    Clin Cancer Res; 2016 Mar; 22(5):1130-7. PubMed ID: 26500237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The genomic landscape of breast cancer brain metastases: a systematic review.
    Morgan AJ; Giannoudis A; Palmieri C
    Lancet Oncol; 2021 Jan; 22(1):e7-e17. PubMed ID: 33387511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
    Han C; Zou H; Ma J; Zhou Y; Zhao J
    Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of prospective genomic profiling of metastatic breast cancer patients.
    van Geelen CT; Savas P; Teo ZL; Luen SJ; Weng CF; Ko YA; Kuykhoven KS; Caramia F; Salgado R; Francis PA; Dawson SJ; Fox SB; Fellowes A; Loi S
    Breast Cancer Res; 2020 Aug; 22(1):91. PubMed ID: 32811538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of ESR1 Mutations in Single Circulating Tumor Cells on Estrogen Deprivation Therapy but Not in Primary Tumors from Metastatic Luminal Breast Cancer Patients.
    Franken A; Honisch E; Reinhardt F; Meier-Stiegen F; Yang L; Jaschinski S; Esposito I; Alberter B; Polzer B; Huebner H; Fasching PA; Pancholi S; Martin LA; Ruckhaeberle E; Schochter F; Tzschaschel M; Hartkopf AD; Mueller V; Niederacher D; Fehm T; Neubauer H
    J Mol Diagn; 2020 Jan; 22(1):111-121. PubMed ID: 31669227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcome of Surgical Resection vs. Radiotherapy in Brain Metastasis From Colorectal Cancer: A Meta-Analysis.
    Chang Y; Wong CE; Lee PH; Huang CC; Lee JS
    Front Med (Lausanne); 2022; 9():768896. PubMed ID: 35350580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling using the UltraSEEK panel identifies discordancy between paired primary and breast cancer brain metastases and an association with brain metastasis-free survival.
    Giannoudis A; Sartori A; Eastoe L; Zakaria R; Charlton C; Hickson N; Platt-Higgins A; Rudland PS; Irwin D; Jenkinson MD; Palmieri C
    Breast Cancer Res Treat; 2021 Nov; 190(2):241-253. PubMed ID: 34499316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
    Callens C; Driouch K; Boulai A; Tariq Z; Comte A; Berger F; Belin L; Bièche I; Servois V; Legoix P; Bernard V; Baulande S; Chemlali W; Bidard FC; Fourchotte V; Salomon AV; Brain E; Lidereau R; Bachelot T; Saghatchian M; Campone M; Giacchetti S; Zafrani BS; Cottu P
    Genome Med; 2021 Mar; 13(1):44. PubMed ID: 33722295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of KRAS and BRAF mutations in metastatic colorectal cancer patients: A systematic review and meta-analysis based on tumor sidedness and KRAS subtypes.
    Saravani K; Salarzaei M; Parooie F
    Hum Antibodies; 2021; 29(4):275-284. PubMed ID: 34334388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.